Mar 10, 2011
From the Healthcare & Life Sciences Institute
Disclosures Handbook 2009-2010, a handbook now in its eighth year from KPMG's Global Pharmaceuticals practice, analyzes trends in financial reporting across the industry and provides insights from KPMG partners and managers around the world.
Our analysis of 2009 financial reporting data for the largest global pharmaceutical companies shows an increase in reporting risks related to strategic alliances and drug development spending, and limited R&D investment. The industry is shifting towards a more challenging cost-oriented environment amid continuing demand for more innovative medicines.